European Healthcare Technology Investment Banking: 10 Key Structural Drivers Accelerating Lower to Mid Market Growth (2026 to 2030)
- Nelson Advisors
- 2 hours ago
- 15 min read
Executive Summary and Macroeconomic Backdrop
The European healthcare technology landscape has transitioned from the speculative, top line driven environment of the Zero Interest Rate Policy (ZIRP) era into an industrial phase centred on capital efficiency, clinical efficacy and regulatory defensibility. Valued at $96.68 billion in 2025, the European HealthTech sector is projected to reach $222.22 billion by 2030, representing a compound annual growth rate (CAGR) of 18.11%. Concurrently, the European MedTech sector represents an estimated €170 billion market, anchored by a positive net medical device trade balance of €5 billion.
This market expansion is focused primarily in the lower to mid market (LMM), defined as companies generating between €5 million and €50 million in annual recurring revenue (ARR) with enterprise values (EV) ranging from €25 million to €250 million. Comprising over 80% of all corporate entities across European digital health, Health AI, Healthcare IT (HCIT) and medical EdTech, the lower to mid market has become the primary destination for private equity dry powder and strategic corporate mergers and acquisitions (M&A).
Recent capital reallocation patterns underscore this rotation. In the first half of 2025, European healthcare and life sciences transaction value grew 87% year over year to €31.8 billion, even as aggregate deal count contracted by 8%. This pronounced divergence illustrates an institutional flight to quality, with financial sponsors and corporate acquirers concentrating larger capital allocations into defensive, clinically validated and cash generative platforms.
Sponsor buyout deployment in European healthcare expanded by 276% year-over-year to €29.6 billion, propelled by record private capital dry powder, private credit stabilisation and programmatic buy and build consolidation strategies designed to capture valuation arbitrage across fragmented regional markets.
HealthTech & Digital Health Sub-Sector | EV / Revenue Baseline Multiples (2025–2026) | EV / EBITDA Multiples (Profitable Targets) | Primary Valuation Driver & Operational Benchmark |
AI-Native Clinical & Diagnostic Solutions | 6.0x – 8.0x+ | High-teens EBITDA premium | EU AI Act "Glass Box" explainability; clinical workflow integration |
Data Interoperability & EHDS Infrastructure | 5.5x – 7.0x | 12.0x – 15.0x | Compliance with Regulation (EU) 2025/327; clean real-world data curation |
Reimbursed Digital Therapeutics (DTx) & Care | 5.5x – 7.0x | 11.0x – 14.0x | Codified payer reimbursement (DiGA, PECAN); proven pathway savings |
Operational Health IT & Workforce Software | 3.5x – 5.0x | 16.0x – 22.0x | Mission-critical back-office workflows; net revenue retention >110% |
Specialist Medical EdTech & Simulation | 4.0x – 6.0x | 11.0x – 14.0x | B2B enterprise hospital contracts; CME accreditation locks |
MedTech Hardware & Connected Devices | 2.5x – 4.5x | 10.0x – 15.0x | Secured MDR/IVDR certification; high-margin recurring consumable revenue |
General Technology Sector Benchmark | 3.5x baseline | 9.0x – 11.0x | Macro tech market comparative baseline across European mid-market |
Unprofitable / Sub-Scale Software Assets | 3.0x – 4.0x | Not Applicable (Negative) | Severe cash-burn penalties; candidates for distressed consolidation |
The structural outperformance of European lower to mid market HealthTech rests upon ten interconnected investment banking drivers that will govern transaction velocity, capital deployment and corporate finance valuations over the next two to five years.
Ten Catalysts Driving Lower to Mid Market Growth
1. Demographic Deficit: The One-Million Clinician Shortfall Driving Mission-Critical Automation
The European healthcare delivery architecture is confronting a severe labor supply contraction. Regional projections from the World Health Organisation (WHO) indicate an impending shortfall of approximately 940,000 to 1,000,000 healthcare professionals across Europe by 2030. This supply constraint is accelerated by an aging clinical demographic: approximately 40% of practicing medical doctors in one-third of European countries are approaching retirement, while nearly one in three European physicians is older than 55 years.
Compounding these structural retirements is persistent clinical burnout. Comprehensive pan-European clinician surveys indicate that one in four physicians routinely works more than 50 hours per week, with 11% to 34% of active healthcare practitioners actively contemplating leaving clinical practice. Because European public health budgets cannot accommodate escalating public sector wage inflation, health ministries, regional hospital groups and primary care networks are treating labour substituting technology as an operational imperative rather than discretionary capital expenditure.
Capital deployment has shifted away from consumer facing wellness tools toward software that automates clinical documentation and administration. Lower to mid market software providers delivering ambient clinical voice intelligence, algorithmic triage, automated clinical note generation and predictive scheduling are achieving rapid enterprise adoption.
In primary care, ambient AI tools have quickly transitioned from pilot trials to widespread deployment, securing significant market penetration across the United Kingdom and Northwestern Europe. By automating the estimated 20% to 35% of clinical time consumed by routine administration, these applications unlock provider capacity without requiring incremental staff recruitment. Consequently, lower to mid market software targets that reduce clinical documentation burdens command premium valuations, trading at baseline enterprise multiples between 5.5x and 7.5x revenue.
2. Regulatory Darwinism: The EU AI Act and the "Glass Box" Valuation Premium
The formal implementation timeline of the European Union Artificial Intelligence Act (EU AI Act) has introduced an institutional filter into the European technology landscape. With high risk medical AI enforcement taking full effect by August 2026, software deploying algorithms for diagnostic triage, patient monitoring, or therapeutic decision support is subject to strict conformity assessments, data quality standards and post-market clinical surveillance.
In corporate M&A and private equity due diligence, this framework has catalysed a trend termed "Regulatory Darwinism". Unbacked algorithmic models, frequently characterised as generic large language model (LLM) wrappers with unexplainable, "Black Box" decision trees, face valuation discounts or complete deal abandonment.
Conversely, clinically validated, proprietary, explainable "Glass Box" AI architectures designed to satisfy EU AI Act compliance are securing valuation premiums of up to 35% over legacy healthcare software peers.
Regulatory Architecture | Implementation Horizon | Legal Mandate & Core Requirement | Direct Impact on Lower to Mid Market M&A |
EU Artificial Intelligence Act | August 2026 Enforcement | High-risk classification for clinical diagnostic/triage algorithms; mandatory algorithmic explainability and audit trails | Penalizes unexplainable API wrappers; grants 35% valuation premiums to compliant "Glass Box" assets |
European Health Data Space (EHDS) | Regulation (EU) 2025/327; phased 2025–2029 | Mandatory cross-border interoperability; centralized secondary data access via HDABs | Unlocks pan-European TAMs; interoperability layers and data cleaning platforms command 5.5x–7.0x revenue |
EU MDR & IVDR | Full phased transition active | Stringent clinical evaluation, notified body re-certification, post-market clinical follow-up | Compliance burdens force under-capitalized SME roll-ups into scaled mid-market PE platforms |
Digital Health Reimbursement (DiGA/PECAN) | Active; cross-border mutual recognition advancing | Fast-tracked statutory reimbursement based on comparative health-economic outcome evidence | De-risks B2B commercial go-to-market; provides visible public payer ARR for buyout underwriting |
Institutional acquirers treat verified regulatory approvals as durable commercial moats. Lower-to-mid-market companies that have navigated notified body audits under the Medical Device Regulation (MDR) or In Vitro Diagnostic Regulation (IVDR) alongside AI Act compliance represent de-risked commercialisation assets for global acquirers.
Strategic acquirers such as Siemens Healthineers, Philips, and Medtronic are acquiring specialised lower to mid market European AI assets to integrate validated algorithms into their existing imaging and informatics suites, bypassing multi-year internal development cycles and regulatory backlogs.
3. Pan-European Scaling Unlocked by the European Health Data Space (EHDS)
European healthcare software companies have historically traded at valuation discounts relative to their North American peers due to market fragmentation. Expanding across borders required re-architecting software to meet localised electronic health record (EHR) standards, varied national IT frameworks and disparate member state interpretations of General Data Protection Regulation (GDPR) mandates.
The enactment of the European Health Data Space (EHDS) under Regulation (EU) 2025/327 fundamentally alters this dynamic. By establishing standardised European Electronic Health Record Exchange Formats (EEHRxF) and setting uniform rules for primary and secondary health data utilisation across all 27 EU member states, the EHDS eliminates the localised technical barriers that once confined software developers to their domestic markets. Implementing acts scheduled between 2025 and 2027 lay the foundation for mandatory cross border EHR interoperability by 2029, expanding the total addressable market (TAM) for lower to mid market platforms from individual domestic systems to a unified market of over 450 million citizens.
This shift has driven acquisition interest in companies operating within the critical data infrastructure layer. Financial sponsors and strategic buyers are targeting middleware providers that translate legacy protocols into standardised FHIR formats, automated data pseudonymisation engines that facilitate secondary clinical research and gateway management systems designed for national Health Data Access Bodies (HDABs).
Lower to mid market targets that enable cross-border health data interoperability currently trade at multiples between 5.5x and 7.0x revenue, supported by their capacity to execute international rollouts without extensive codebase modification.
4. Sponsor Buy and Build Playbooks and Institutional Multiple Arbitrage
Global healthcare private equity activity reached $191 billion in disclosed deal value in 2025, while European healthcare buyout value doubled to $59 billion. Within the European lower-to-mid market, financial sponsors have deployed record levels of dry powder through programmatic buy-and-build consolidation strategies to achieve valuation multiple arbitrage.
Under this investment thesis, a private equity sponsor acquires an established regional software business generating between €15 million and €40 million in revenue and €3 million to €8 million in EBITDA at an entry valuation of 10.0x to 12.0x EV/EBITDA. The sponsor then executes programmatic bolt-on acquisitions of founder-led, specialised software products or adjacent regional vendors at lower entry multiples of 6.0x to 8.0x EV/EBITDA. By centralising corporate administration, migrating disparate IT environments to unified cloud infrastructure, and cross-selling product modules across an expanded client base, the sponsor accelerates earnings growth while expanding the company's geographic footprint. The consolidated enterprise is ultimately exited to an upper middle market sponsor, infrastructure fund, or corporate strategic buyer at an expanded valuation multiple of 14.0x to 18.0x+ EV/EBITDA.
Enterprise software investors such as Main Capital Partners have demonstrated this playbook through platform transactions in critical care communications and clinical scheduling. Platforms like POLYPOINT (healthcare workforce management in the DACH region) and IQ Messenger (vendor-neutral critical alarms and clinical communications in Benelux) serve as consolidators of fragmented point solutions across Northwestern Europe.
Similar sponsor roll ups are accelerating across pathology, laboratory information systems (LIS), and radiology workflows, with mid market platforms offering cash flow visibility that supports sustainable debt service in leveraged buyout structures.
5. Post ZIRP Capital Realignment and the "Series B Bottleneck"
The macroeconomic shift away from zero interest rates restructured the late-stage funding environment for European venture-backed digital health firms. During the market peak of 2020–2021, emerging digital health companies targeted initial public offerings (IPOs) as their primary terminal liquidity event. By 2025, public equity markets had closed to unprofitable, mid-scale technology businesses, resulting in M&A representing more than 94% of all digital health exits globally.
European venture capital funds face persistent liquidity pressures, with net cash distributions turning negative in 2024 and compelling fund managers to seek programmatic trade sales over dilutive follow-on growth rounds.
Total digital health venture funding contracted from a peak of $29.1 billion in 2021 to $12.6 billion in 2023, leaving late-stage, high-burn companies without adequate follow-on capital. This contraction produced a market condition termed the "Series B bottleneck," characterised by an 84% reduction in available Series B capital compared to 2021.
Venture Metric & Stage Filter | Historical Paradigm (2020–2021 Peak) | Modern Realignment (2025–2026 Environment) |
Dominant Liquidity Channel | IPOs accounted for 94% of total realized exit value | Strategic M&A and PE buyouts represent 94.7% of all exits |
Seed-to-Series A Interval | Approximately 12 to 15 months; rapid capital deployment | Lengthened to an average of 774 days |
Internal Bridge Round Frequency | <15% of active venture portfolio companies | Escalated to ~37% of venture rounds |
Series B Growth Capital Access | Open capital access; high top-line revenue multiples | Compressed down 84% relative to 2021 high points |
Founding Team Exit Orientation | Late-stage IPO trajectory; speculative cash-burn targets | "Series A/B Off-Ramps": M&A exits to PE platforms at €25M–€75M EV |
The average duration between Seed and Series A financings has lengthened to 774 days, while internal bridge rounds now account for approximately 37% of venture transactions. Consequently, corporate finance advisers are actively executing structured "Series A and Series B off-ramps".
High-performing companies that have attained product-market fit, achieved between €5 million and €15 million in ARR and reached operating breakeven are exiting via structured trade sales to private equity platforms or strategic acquirers at enterprise values of €25 million to €75 million, supplying the lower to mid market with acquisition targets at attractive entry valuations.
6. Hospital CIO Point Solution Fatigue and Platform Rationalisation
European hospital chief information officers (CIOs), clinical informatics heads, and regional health trusts are dealing with acute "point solution fatigue". Over the past decade, healthcare providers procured dozens of disconnected software applications for remote patient monitoring, specialty consultations, appointment scheduling and departmental charting. This proliferation generated heavy software maintenance costs, fragmented clinical data across isolated silos and expanded cyber-attack vectors across hospital networks.
Hospital procurement executives and Integrated Care Systems (ICSs) across Europe are rationalising vendor rosters, favouring unified, multi-functional enterprise platforms over standalone point solutions. This procurement shift requires lower to mid market software companies to broaden their functional reach or face displacement. Niche digital health businesses, such as standalone digital musculoskeletal (MSK) therapy, tele-ophthalmology, or remote vital tracking are executing cross-specialty mergers to build comprehensive care management platforms capable of competing for enterprise provider contracts.
Concurrently, pan European hospital information system (HIS) incumbents, including Dedalus Group (backed by Ardian), CompuGroup Medical and Nexus AG (backed by TA Associates), are using strategic M&A to absorb niche capabilities.
By acquiring specialist software providers across patient engagement, laboratory software, and clinical communication, these platform operators embed niche functionality directly into their core Electronic Medical Record (EMR) architectures, protecting their market position and expanding wallet share across existing client accounts.
7. Codification of Statutory Digital Health Reimbursement Pathways
A historical impediment to scaling European digital health businesses was the lack of formal public reimbursement mechanisms, which forced early applications to rely on out of pocket consumer payments or bespoke employer benefit schemes. The statutory codification of dedicated digital health reimbursement pathways has established clear routes to institutional revenue generation.
Following Germany's rollout of the Digital Healthcare Act (DVG) and its DiGA (Digitale Gesundheitsanwendungen) registry, France introduced its PECAN (Prise en charge anticipée numérique) fast-track framework. Similar value-based digital health reimbursement structures are active or advancing across Belgium (mHealthBelgium), Austria and the Nordic markets. These systems allow accredited digital health solutions to be prescribed directly by licensed clinicians, with reimbursement funded through statutory health insurance and national sickness funds.
For financial underwriters, codified reimbursement frameworks transform early stage digital health applications into predictable, public payer backed recurring revenue streams. Securing permanent reimbursement requires clinical evidence demonstrating health economic utility or patient outcome improvements.
Companies that clear these regulatory and evidence thresholds establish substantial competitive barriers to entry. In lower to mid market transactions, reimbursed digital therapeutics and care platforms command enterprise multiples between 5.5x and 7.0x revenue and 11.0x to 14.0x EBITDA, compared to 2.0x to 3.5x for non-reimbursed consumer health assets.
8. Public Procurement Overhauls: The UK NHS 10-Year Plan and Sovereign IT Mandates
European public health authorities are overhauling legacy procurement structures, shifting away from localised lowest cost tendering toward centralised, value-based procurement. The clearest example of this policy shift is the United Kingdom's NHS 10 Year Health Plan ("Fit for the Future"), which sets out long-term strategic shifts: transferring care delivery from acute hospitals to neighbourhood community settings, moving from analog documentation to integrated digital systems and shifting clinical focus from reactive sickness treatment to proactive prevention.
The UK government has committed a £29 billion real-terms increase in day to day NHS spending, supported by a ring-fenced £10 billion digital and IT infrastructure budget. The plan mandates that NHS trusts reserve up to 3% of their budgets specifically for technological transformation, generating approximately £6 billion annually for digital deployments.
National Strategic Initiative | Legislative / Fiscal Mechanism | Dedicated Capital Allocation | Target Technology Infrastructure |
UK NHS 10-Year Health Plan | "Fit for the Future" Health Reform Mandate | £10B baseline IT budget; £6B annual transformation set-aside (3% budget) | National Ambient AI Procurement Framework; Single Patient Record (SPR); expanded NHS App front door |
NHS Ambient AI Framework | Centralized Procurement Pipeline (2026/2027) | Central multi-trust commercial procurement agreements | Ambient clinical voice dictation, automated clinical scribing, acute triage automation |
Data (Use and Access) Act 2025 | Mandated National Health Data Standards | Statutory compliance capital across primary/secondary care | Interoperable Electronic Patient Records (EPR), open API architectures, secure data silos |
Regional Health Innovation Zones | Devolved procurement powers to local trusts and ICSs | Local discretionary commissioning funds | Payment-for-outcomes contracting; rapid-adoption "Innovator Passports" |
Centralised frameworks accelerate enterprise sales velocity for lower-to-mid-market companies. Historically, selling into the NHS required commercial campaigns across 215 individual hospital trusts and 42 Integrated Care Systems, with sales cycles regularly stretching to 24 months.
Under streamlined national frameworks, an "innovator passport" permitting trust to trust procurement portability, and central repositories like the NHS HealthStore, lower to mid market software vendors with validated clinical utility can scale across regional delivery systems. This procurement model removes sales friction and underpins revenue growth across the UK Health IT landscape.
9. Safety Critical Medical EdTech, Workforce Re-skilling and Procedural Simulation
While general consumer EdTech has experienced valuation compression and public market corrections, specialised healthcare and medical EdTech has attracted sustained institutional capital. Facing persistent clinical staffing deficits and increasing surgical complexity, healthcare systems consider medical training platforms essential operational infrastructure rather than discretionary educational software.
Medical training software addresses the full lifecycle of healthcare professionals, covering medical exam preparation, continuous medical education (CME), nursing re-credentialing and surgical simulation. European healthcare providers are utilising digital learning and simulation platforms to shorten the onboarding timeline for foreign trained clinicians and cross train existing nursing rosters into acute care environments.
These platforms exhibit recurring, resilient corporate finance metrics. Digital knowledge platforms like AMBOSS and Lecturio have built defensible clinical knowledge bases, supporting medical professionals through enterprise B2B subscription contracts with universities, hospital groups and academic networks. In virtual reality (VR) and mixed-reality simulation, companies such as FundamentalVR and Inovus Medical are securing growth capital by demonstrating that hands on digital simulations lower procedural error rates in the operating room.
Private equity sponsors are executing roll-ups of specialised CME and clinical simulation assets, illustrated by Levine Leichtman Capital Partners' investment in Improve International, attracted by their high customer retention, contractual pricing power, and negative net churn profiles. In M&A transactions, specialised medical training and clinical simulation targets trade at valuations between 4.0x and 6.0x revenue and 11.0x to 14.0x EBITDA.
10. AI Native Unit Economics: ARR per FTE Decoupling and Structural Margin Expansion
The structural transition from legacy Software-as-a-Service (SaaS) architectures to AI native systems is resetting operating leverage in healthcare technology. In historical software models, revenue expansion required proportional headcount growth to handle customer onboarding, data integration, professional services and administrative support. In contrast, AI native platforms are decoupling enterprise revenue scale from internal employee headcount.
Operational Metric & Financial Benchmark | Traditional Healthcare Services | Legacy Pre-AI Healthcare SaaS | AI-Native Digital Health Platforms (2025–2026) |
ARR generated per Full-Time Employee (FTE) | $100,000 – $200,000 | $200,000 – $400,000 | $500,000 – $1,000,000+ |
Gross Margin Profile | 25% – 40% | 65% – 75% | 75% – 85%+ |
Rule of 40 Institutional Profile | Rare (<10% of entities) | Attainable at operational scale | Structural Standard (FCF Margin + Rev Growth >40%) |
Customer Implementation Timelines | 6 – 12 months manual services | 3 – 6 months specialized IT | 1 – 4 weeks via automated API integrations |
EBITDA Margin at Maturity | 10% – 15% | 20% – 25% | 30% – 40%+ |
By deploying agentic AI across customer implementation, workflow customisation, and clinical data extraction, AI native platforms are generating ARR per FTE metrics between $500,000 and $1,000,000+, compared to the $200,000 to $400,000 typical of legacy healthcare SaaS platforms.
This operational leverage improves leveraged buyout (LBO) underwriting mechanics for private equity acquirers. Software targets operating with gross margins above 80% and low capital expenditures achieve high free cash flow conversion rates. These financial profiles permit financial sponsors to support leveraged debt structures comfortably while allowing target companies to exceed the "Rule of 40" benchmark.
As financial buyers compete for assets capable of delivering profitable, cash generative expansion, these AI-native software targets command top-tier baseline valuation multiples between 6.0x and 8.0x+ revenue in lower to mid-market M&A processes.
Regional M&A Specialisation and Transaction Dynamics
Consolidation across the European lower-to-mid-market healthcare technology sector displays distinct regional patterns, shaped by differences in national reimbursement structures, healthcare IT maturity and local private equity presence.
The United Kingdom represents the fastest-growing market by transaction value in European Health IT. Driven by dedicated NHS transformation funding and private capital investment in primary care digitisation, the UK operates as the primary European market for administrative AI, ambient scribing and outpatient virtual care platforms.
The DACH region (Germany, Austria, Switzerland) serves as the primary European center for MedTech hardware roll-ups, laboratory software systems, and hospital enterprise IT consolidation. DACH MedTech transactions average roughly 160 deals annually, with targets trading at EV/EBITDA multiples between 6.0x and 13.0x. Strategic buyout transactions, including TA Associates' tender offer for Nexus AG and Main Capital Partners' acquisition of POLYPOINT, illustrate buyer appetite for mission-critical, recurring clinical software platforms.
In the Nordic markets (Sweden, Denmark, Finland, Norway), highly digitised public healthcare infrastructure supports the commercial testing of remote patient monitoring, home healthcare delivery, and AI diagnostic platforms, with Sweden's home healthcare technology segment projected to reach $8.1 billion by 2030. Southern Europe and France are capturing an increasing share of transaction volume. France recorded a 45% increase in M&A transaction value, supported by its PECAN digital health reimbursement framework, while the Spanish and Italian markets remain active centres for clinic roll-ups spanning dental, ophthalmology, and specialised diagnostics.
Investment Banking Valuation Matrix and Exit Outlook
The convergence of clinical staffing shortages, regulatory frameworks, pan-European data harmonisation, and substantial private equity dry powder positions the European lower to mid market for accelerated growth and sustained transaction velocity over the next two to five years.
These market conditions have transformed lower to mid market investment banking advisory from basic corporate brokerage into a specialised discipline requiring clinical, regulatory and financial modelling expertise. Because bulge-bracket investment banks focus on mega transactions exceeding €1 billion and local generalist brokers often lack technical and clinical depth, specialised sector boutiques fill an essential institutional advisory role in the €25 million to €250 million enterprise value range.
Lower to mid market M&A activity will remain selective. The market will continue to penalise unprofitable point solutions and unshielded API wrappers, compressing their valuation multiples toward distressed sale levels. Conversely, platforms that demonstrate clinical efficacy, regulatory compliance under the EU AI Act, automated cross-border interoperability via the EHDS and strong unit economics will continue to command premium valuations. These businesses will lead the consolidation wave, establishing the operational foundation of European healthcare delivery through 2030 and beyond.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments